公开(公告)号：US10899753B2

公开(公告)日：2021-01-26

申请号：US16410725

申请日：2019-05-13

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Robin Prince ,  Isaac Marx ,  Jürgen Schulz ,  Marta Nevalainen ,  Michael Dechantsreiter

IPC: C07D413/14 ,  C07D403/14 ,  C07D405/14

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US20240083900A1

公开(公告)日：2024-03-14

申请号：US18036853

申请日：2021-11-12

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Isaac Marx ,  Jürgen Schulz ,  George Vandeveer ,  Robin Prince ,  Marta Nevalainen ,  TeYu Chen ,  Zain Yousaf ,  Martin Himmelbauer ,  Vatee Pattaropong ,  John Howard Jones ,  Edward Yin-Shiang Lin ,  Felix Gonzalez Lopez de Turiso ,  Thomas Purgett ,  Andrew George Capacci ,  Simone Sciabola

IPC: C07D487/04 ,  C07D471/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D519/00

Abstract: Provided are compounds of Formula (I′): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.

公开(公告)号：US20190382394A1

公开(公告)日：2019-12-19

申请号：US16410725

申请日：2019-05-13

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Robin Prince ,  Isaac Marx ,  Jürgen Schulz ,  Marta Nevalainen ,  Michael Dechantsreiter

IPC: C07D413/14 ,  C07D405/14 ,  C07D403/14

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US20240287076A1

公开(公告)日：2024-08-29

申请号：US18289438

申请日：2022-05-05

Applicant: BIOGEN MA INC. ,  C4 THERAPEUTICS, INC.

Inventor： Kevin M. Guckian ,  Eric Stefan ,  Corey Don Anderson ,  Jae Young Ahn ,  Morgan Welzel O'Shea ,  Jeremy L. Yap ,  Xinpeng Cheng ,  Brian T. Hopkins ,  Isaac Marx ,  Marta Nevalainen

IPC: C07D487/04 ,  A61K31/53

CPC classification number: C07D487/04 ,  A61K31/53

Abstract: This disclosure relates to compounds of Formula (A): BTK-L-DSM (A) or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches BTK to DSM, and BTK is a Btk binding moiety represented by Formula (I) or Formula (II) that is covalently attached to linker L: in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of Btk proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of Btk proteins. The present disclosure also provides methods of treating disorders responsive to modulation of Btk activity and/or degradation of Btk with at least one compound described herein.

公开(公告)号：US20220411429A1

公开(公告)日：2022-12-29

申请号：US17773471

申请日：2020-10-29

Applicant: BIOGEN MA INC.

Inventor： Isaac Marx ,  Jürgen Schulz ,  Brian T. Hopkins ,  Bin Ma ,  Robin Prince ,  Marta Nevalainen

IPC: C07D487/04 ,  C07D519/00

Abstract: Provided are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein ring A, R3, R4, R5, R6, A1, B1, B2, Q1 and Q2 are as defined herein; and methods for their use and production.

公开(公告)号：US20250090524A1

公开(公告)日：2025-03-20

申请号：US18709268

申请日：2022-11-11

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  BIn Ma ,  Jürgen Schulz ,  Marta Nevalainen ,  TeYu Chen ,  Robin J. Prince ,  Harold George Vandeveer ,  Issac Marx ,  Simone Sciaboba ,  Edward Yin Shiang Lin

IPC: A61K31/4985 ,  A61K31/437 ,  A61K31/55 ,  C07D471/04 ,  C07D487/04

Abstract: Provided are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables in Formula (I) are as defined herein; and methods for their use and production.

公开(公告)号：US12240838B2

公开(公告)日：2025-03-04

申请号：US17610963

申请日：2020-05-15

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Robin Prince ,  Isaac Marx ,  Jürgen Schulz ,  Marta Nevalainen

IPC: C07D413/12 ,  C07D401/12 ,  C07D413/14 ,  C07D417/12

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US20250034150A1

公开(公告)日：2025-01-30

申请号：US18709273

申请日：2022-11-10

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Jürgen Schulz ,  Marta Nevalainen ,  TeYu Chen ,  Robin Prince ,  Harold George Vandeveer ,  Isaac Marx ,  Simone Sciabola ,  Zain Yousaf

IPC: C07D487/04 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  C07D471/04 ,  C07D519/00

Abstract: Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables in Formula (I) are as defined herein; and methods for their use and production.

公开(公告)号：US20240327380A1

公开(公告)日：2024-10-03

申请号：US18019540

申请日：2021-08-05

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Isaac Marx ,  Jürgen Schulz ,  Harold George Vandeveer ,  Robin Prince ,  Marta Nevalainen ,  TeYu Chen ,  Zain Yousaf ,  Martin Himmelbauer ,  Vatee Pattaropong ,  John Howard Jones ,  Rab Gilfillan ,  Edward Yin Shiang Lin ,  Felix Gonzalez Lopez de Turiso ,  Bin Ma

IPC: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/10

CPC classification number: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/10

Abstract: Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R7, R8, R9, A1, A2, Q1, Q2, Q3, A, Z, m and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.

公开(公告)号：US20230121818A1

公开(公告)日：2023-04-20

申请号：US17788127

申请日：2020-12-23

Applicant: BIOGEN MA INC.

Inventor： Bin Ma ,  Brian T. Hopkins ,  Isaac Marx ,  Jürgen Schulz ,  George Vandeveer ,  Robin Prince ,  Marta Nevalainen ,  TeYu Chen ,  Zain Yousaf ,  Andrew George Capacci

IPC: C07D401/14 ,  C07D413/12 ,  C07D471/04 ,  C07D403/12 ,  C07D403/10 ,  C07D495/04 ,  C07D401/12 ,  C07D413/14

Abstract: Provided are compounds of Formula (I′) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R8, R9, R11A, R11B, R12, Ri, Rii, A1, A2, Q1, Q2, Q3, X, W, and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.